Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer

Brief summary (registry, in English)

To determine the diagnostic accuracy of 18F-PSMA PET/MRI for the diagnosis of clinically relevant prostate cancer

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 167
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 18 or older who are suspected of having prostate cancer that matters clinically. It tests how well a 18F-PSMA PET/MRI scan finds this cancer.

Age

18 years or older

Sex

Men only

Disease stage

Suspected clinically significant prostate cancer, not yet diagnosed

Main reasons for not taking part

• Already diagnosed with prostate cancer
• Cannot have an MRI scan (for example claustrophobia, pacemaker, estimated GFR of 50 mls/min or less)
• Cannot have a prostate biopsy

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details